FDA Approves Afinitor Disperz to Shrink Brain Tumors in Children

Afinitor has previously been used as an anti-cancer drug in adults. It’s goal is to treat a rare brain tumor – subependymal giant cell astrocytoma – commonly known as SEGA. Afinitor Disperz is the adapted pediatric-specific dosage.

Afinitor Disperz should be given to patients around 1-years-old with tuberous sclerosis complez (TSC), a rare genetic disease leading to tumors growing in the brain and other organs. SEGA is usually a major diagnostic feature of TSC. We see it in 6%-9% of patients, generally pediatric and sometimes young adult.

Afinitor Disperz, and other similar drugs, “help to ensure the safe and effective use of oncology drugs in children,” said Richard Pazdur, MD.

The drug dissolves easily, so it can be given to young patients without a problem.

During a recent study, 117 patients were randomly assigned Afinitor or a placebo. Out of the patients who received the drug, 35% showed tumor shrinkage.

SEGA often leads to respiratory tract infections and mouth ulcers.

The medication works because of its Everolimus ingredient, which blocks the mTOR kinase protein. That protein is responsible for the growth of SEGA tumors.

Cedar Lake is equipped to help patients with this type of cancer and interested patients can learn more on the website.

For the article on Afinitor Disperz, click here.